This is a randomized, double-blind, placebo-controlled, 2-arm parallel group study. After
qualifying for the study and signing informed consent, patients will undergo a two-week
observation period during which stool consistency and frequency data and symptom data will be
collected. Patients will then be randomized 60:40 to RHB-102 12 mg (BEKINDA) or placebo.
Patients will continue on treatment for 8 weeks. Each medication will be given once daily.